Cargando…

Mitochondrial Aldehyde Dehydrogenase 2 Represents a Potential Biomarker of Biochemical Recurrence in Prostate Cancer Patients

Background: We aimed to explore the role of mitochondrial aldehyde dehydrogenase 2 (ALDH2) in prostate cancer (PCa) patients and provide insights into the tumor immune microenvironment (TME) for those patients undergoing radical radiotherapy. Methods: We performed all analyses using R version 3.6.3...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Dechao, Zhu, Weizhen, You, Jia, Shi, Xu, Han, Ping, Wei, Wuran, Wei, Qiang, Yang, Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500792/
https://www.ncbi.nlm.nih.gov/pubmed/36144737
http://dx.doi.org/10.3390/molecules27186000
_version_ 1784795309545619456
author Feng, Dechao
Zhu, Weizhen
You, Jia
Shi, Xu
Han, Ping
Wei, Wuran
Wei, Qiang
Yang, Lu
author_facet Feng, Dechao
Zhu, Weizhen
You, Jia
Shi, Xu
Han, Ping
Wei, Wuran
Wei, Qiang
Yang, Lu
author_sort Feng, Dechao
collection PubMed
description Background: We aimed to explore the role of mitochondrial aldehyde dehydrogenase 2 (ALDH2) in prostate cancer (PCa) patients and provide insights into the tumor immune microenvironment (TME) for those patients undergoing radical radiotherapy. Methods: We performed all analyses using R version 3.6.3 and its suitable packages. Cytoscape 3.8.2 was used to establish network of competing endogenous RNAs (ceRNAs). Results: Downregulation of ADLH2 was significantly associated with higher risk of BCR-free survival (HR: 0.40, 95%CI: 0.24–0.68, p = 0.001) and metastasis-free survival (HR: 0.21, 95%CI: 0.09–0.49, p = 0.002). Additionally, ALDH2 repression contributed to significantly shorter BCR-free survival in the TCGA database (HR: 0.55, 95%CI: 0.33–0.93, p = 0.027). For immune checkpoints, patients that expressed a higher level of CD96 had a higher risk of BCR than their counterparts (HR: 1.79, 95%CI: 1.06–3.03, p = 0.032), as well as NRP1 (HR: 2.18, 95%CI: 1.29–3.69, p = 0.005). In terms of the TME parameters, the spearman analysis showed that ALDH was positively associated with B cells (r: 0.13), CD8+ T cells (r: 0.19), neutrophils (r: 0.13), and macrophages (r: 0.17). Patients with higher score of neutrophils (HR: 1.75, 95%CI: 1.03–2.95, p = 0.038), immune score (HR: 1.92, 95%CI: 1.14–3.25, p = 0.017), stromal score (HR: 2.52, 95%CI: 1.49–4.26, p = 0.001), and estimate score (HR: 1.81, 95%CI: 1.07–3.06, p = 0.028) had higher risk of BCR than their counterparts. Our ceRNA network found that PART1 might regulate the expression of ALDH via has-miR-578 and has-miR-6833-3p. Besides, PHA-793887, PI-103, and piperlongumine had better correlations with ALDH2. Conclusions: We found that ALDH2 might serve as a potential biomarker predicting biochemical recurrence for PCa patients.
format Online
Article
Text
id pubmed-9500792
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95007922022-09-24 Mitochondrial Aldehyde Dehydrogenase 2 Represents a Potential Biomarker of Biochemical Recurrence in Prostate Cancer Patients Feng, Dechao Zhu, Weizhen You, Jia Shi, Xu Han, Ping Wei, Wuran Wei, Qiang Yang, Lu Molecules Article Background: We aimed to explore the role of mitochondrial aldehyde dehydrogenase 2 (ALDH2) in prostate cancer (PCa) patients and provide insights into the tumor immune microenvironment (TME) for those patients undergoing radical radiotherapy. Methods: We performed all analyses using R version 3.6.3 and its suitable packages. Cytoscape 3.8.2 was used to establish network of competing endogenous RNAs (ceRNAs). Results: Downregulation of ADLH2 was significantly associated with higher risk of BCR-free survival (HR: 0.40, 95%CI: 0.24–0.68, p = 0.001) and metastasis-free survival (HR: 0.21, 95%CI: 0.09–0.49, p = 0.002). Additionally, ALDH2 repression contributed to significantly shorter BCR-free survival in the TCGA database (HR: 0.55, 95%CI: 0.33–0.93, p = 0.027). For immune checkpoints, patients that expressed a higher level of CD96 had a higher risk of BCR than their counterparts (HR: 1.79, 95%CI: 1.06–3.03, p = 0.032), as well as NRP1 (HR: 2.18, 95%CI: 1.29–3.69, p = 0.005). In terms of the TME parameters, the spearman analysis showed that ALDH was positively associated with B cells (r: 0.13), CD8+ T cells (r: 0.19), neutrophils (r: 0.13), and macrophages (r: 0.17). Patients with higher score of neutrophils (HR: 1.75, 95%CI: 1.03–2.95, p = 0.038), immune score (HR: 1.92, 95%CI: 1.14–3.25, p = 0.017), stromal score (HR: 2.52, 95%CI: 1.49–4.26, p = 0.001), and estimate score (HR: 1.81, 95%CI: 1.07–3.06, p = 0.028) had higher risk of BCR than their counterparts. Our ceRNA network found that PART1 might regulate the expression of ALDH via has-miR-578 and has-miR-6833-3p. Besides, PHA-793887, PI-103, and piperlongumine had better correlations with ALDH2. Conclusions: We found that ALDH2 might serve as a potential biomarker predicting biochemical recurrence for PCa patients. MDPI 2022-09-15 /pmc/articles/PMC9500792/ /pubmed/36144737 http://dx.doi.org/10.3390/molecules27186000 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Feng, Dechao
Zhu, Weizhen
You, Jia
Shi, Xu
Han, Ping
Wei, Wuran
Wei, Qiang
Yang, Lu
Mitochondrial Aldehyde Dehydrogenase 2 Represents a Potential Biomarker of Biochemical Recurrence in Prostate Cancer Patients
title Mitochondrial Aldehyde Dehydrogenase 2 Represents a Potential Biomarker of Biochemical Recurrence in Prostate Cancer Patients
title_full Mitochondrial Aldehyde Dehydrogenase 2 Represents a Potential Biomarker of Biochemical Recurrence in Prostate Cancer Patients
title_fullStr Mitochondrial Aldehyde Dehydrogenase 2 Represents a Potential Biomarker of Biochemical Recurrence in Prostate Cancer Patients
title_full_unstemmed Mitochondrial Aldehyde Dehydrogenase 2 Represents a Potential Biomarker of Biochemical Recurrence in Prostate Cancer Patients
title_short Mitochondrial Aldehyde Dehydrogenase 2 Represents a Potential Biomarker of Biochemical Recurrence in Prostate Cancer Patients
title_sort mitochondrial aldehyde dehydrogenase 2 represents a potential biomarker of biochemical recurrence in prostate cancer patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500792/
https://www.ncbi.nlm.nih.gov/pubmed/36144737
http://dx.doi.org/10.3390/molecules27186000
work_keys_str_mv AT fengdechao mitochondrialaldehydedehydrogenase2representsapotentialbiomarkerofbiochemicalrecurrenceinprostatecancerpatients
AT zhuweizhen mitochondrialaldehydedehydrogenase2representsapotentialbiomarkerofbiochemicalrecurrenceinprostatecancerpatients
AT youjia mitochondrialaldehydedehydrogenase2representsapotentialbiomarkerofbiochemicalrecurrenceinprostatecancerpatients
AT shixu mitochondrialaldehydedehydrogenase2representsapotentialbiomarkerofbiochemicalrecurrenceinprostatecancerpatients
AT hanping mitochondrialaldehydedehydrogenase2representsapotentialbiomarkerofbiochemicalrecurrenceinprostatecancerpatients
AT weiwuran mitochondrialaldehydedehydrogenase2representsapotentialbiomarkerofbiochemicalrecurrenceinprostatecancerpatients
AT weiqiang mitochondrialaldehydedehydrogenase2representsapotentialbiomarkerofbiochemicalrecurrenceinprostatecancerpatients
AT yanglu mitochondrialaldehydedehydrogenase2representsapotentialbiomarkerofbiochemicalrecurrenceinprostatecancerpatients